Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians : a population based study
© 2023 The Authors..
Background: Few studies have examined effectiveness of COVID-19 vaccines against COVID-19 and all-cause mortality across different pandemic periods in 2022.
Methods: We used linked whole-of-population data from the 2021 Australian Census, Australian Immunisation Register, death registrations and other national datasets including migration data. Among 3.8 million adults aged 65+ years and >170,000 aged care residents, we used survival analysis to estimate vaccine effectiveness (VE) against COVID-19 specific mortality and all-cause mortality, by vaccine dose and time since receipt, adjusted for age, sex and other factors. We also estimated absolute COVID-19 mortality rates.
Findings: From January-May 2022 (Omicron BA.1/2), 3250 COVID-19 deaths occurred; from June-November (Omicron BA.4/5) 3185 COVID-19 deaths occurred. During January-May, VE of a 3rd COVID-19 vaccine dose within 3 months was 93% (95% CI 93-94%) whilst VE of a 2nd dose >6 months since receipt was 34% (26-42%). During June-November, VE of a 4th COVID-19 vaccine dose within 3 months was 84% (82-86%) whilst VE of a 3rd dose >6 months since receipt was 56% (50-62%). VE estimates for aged care residents were similar, but absolute risk reductions were substantially greater. During June-November 2022, for all-cause mortality, VE of a 4th dose within 3 months was 58% (56-59%) whilst VE of a 3rd dose >6 months since receipt was 19% (16-22%).
Interpretations: COVID-19 vaccination is highly effective against COVID-19 mortality among older adults although effectiveness wanes with time since the last dose. Our findings emphasise the importance of continuing to administer booster doses, particularly to those at highest risk.
Funding: This study was funded by the Health Economics Research Division in the Australian Government Department of Health and Aged Care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
The Lancet regional health. Western Pacific - 40(2023) vom: 12. Nov., Seite 100928 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Bette [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 20.10.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.lanwpc.2023.100928 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363469435 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363469435 | ||
| 003 | DE-627 | ||
| 005 | 20231226093421.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lanwpc.2023.100928 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363469435 | ||
| 035 | |a (NLM)37854458 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Bette |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians |b a population based study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Background: Few studies have examined effectiveness of COVID-19 vaccines against COVID-19 and all-cause mortality across different pandemic periods in 2022 | ||
| 520 | |a Methods: We used linked whole-of-population data from the 2021 Australian Census, Australian Immunisation Register, death registrations and other national datasets including migration data. Among 3.8 million adults aged 65+ years and >170,000 aged care residents, we used survival analysis to estimate vaccine effectiveness (VE) against COVID-19 specific mortality and all-cause mortality, by vaccine dose and time since receipt, adjusted for age, sex and other factors. We also estimated absolute COVID-19 mortality rates | ||
| 520 | |a Findings: From January-May 2022 (Omicron BA.1/2), 3250 COVID-19 deaths occurred; from June-November (Omicron BA.4/5) 3185 COVID-19 deaths occurred. During January-May, VE of a 3rd COVID-19 vaccine dose within 3 months was 93% (95% CI 93-94%) whilst VE of a 2nd dose >6 months since receipt was 34% (26-42%). During June-November, VE of a 4th COVID-19 vaccine dose within 3 months was 84% (82-86%) whilst VE of a 3rd dose >6 months since receipt was 56% (50-62%). VE estimates for aged care residents were similar, but absolute risk reductions were substantially greater. During June-November 2022, for all-cause mortality, VE of a 4th dose within 3 months was 58% (56-59%) whilst VE of a 3rd dose >6 months since receipt was 19% (16-22%) | ||
| 520 | |a Interpretations: COVID-19 vaccination is highly effective against COVID-19 mortality among older adults although effectiveness wanes with time since the last dose. Our findings emphasise the importance of continuing to administer booster doses, particularly to those at highest risk | ||
| 520 | |a Funding: This study was funded by the Health Economics Research Division in the Australian Government Department of Health and Aged Care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Vaccine effectiveness | |
| 650 | 4 | |a Waning effectiveness | |
| 700 | 1 | |a Stepien, Sandrine |e verfasserin |4 aut | |
| 700 | 1 | |a Dobbins, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Gidding, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Henry, David |e verfasserin |4 aut | |
| 700 | 1 | |a Korda, Rosemary |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Pearson, Sallie-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Pratt, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Vajdic, Claire M |e verfasserin |4 aut | |
| 700 | 1 | |a Welsh, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Macartney, Kristine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet regional health. Western Pacific |d 2020 |g 40(2023) vom: 12. Nov., Seite 100928 |w (DE-627)NLM320728897 |x 2666-6065 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g day:12 |g month:11 |g pages:100928 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lanwpc.2023.100928 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |b 12 |c 11 |h 100928 | ||